Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
How to position pasireotide LAR treatment in acromegaly
Eva C. Coopmans
, Ammar Muhammad
, Aart J. Van Der Lely
, Joseph A.M.J.L. Janssen
,
Sebastian J.C.M.M. Neggers
Research output
:
Contribution to journal
›
Review article
›
peer-review
49
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'How to position pasireotide LAR treatment in acromegaly'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pasireotide
100%
Long-term Release
100%
Release Treatment
100%
Pegvisomant
46%
Consensus Criteria
30%
Tumor Growth
23%
Monotherapy
23%
Somatostatin Receptor Ligands
23%
Combination Therapy
15%
Hyperglycemia
15%
Young Patients
7%
Medical Treatment
7%
Headache
7%
Patient with Tumor
7%
Intolerant
7%
Second-line Therapy
7%
Somatostatin
7%
International Journals
7%
Multireceptor
7%
Third-line Treatment
7%
Liberal
7%
Without Diabetes
7%
Clinical Papers
7%
Blood Glucose Monitoring
7%
Combination Studies
7%
Evidence Acquisition
7%
Medicine and Dentistry
Acromegaly
100%
Pasireotide
100%
Pegvisomant
46%
Tumor Progression
23%
Combination Therapy
23%
Monotherapy
23%
Somatostatin Receptor
23%
Hyperglycemia
15%
Side Effect
7%
Headache
7%
Diabetes
7%
Somatostatin
7%
Blood Glucose Monitoring
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acromegaly
100%
Pasireotide
100%
Pegvisomant
46%
Tumor Growth
23%
Combination Therapy
23%
Monotherapy
23%
Somatostatin Receptor
23%
Hyperglycemia
15%
Side Effect
7%
Headache
7%
Somatostatin
7%